Sustained ventricular arrhythmia and sinus node dysfunction revealing a cardiac amyloidosis: A case report.

Ann Med Surg (Lond)

Dept. of Cardiology A - National Cardiovascular League, Ibn Sina University Hospital Center, Mohammed V University, Rabat, Morocco.

Published: December 2022

Introduction And Importance: Amyloidosis is an infiltrative multisystem disease due to extracellular deposition of fibrils in tissues and organs. Cardiac involvement can result in progressive heart failure, conduction abnormalities and arrhythmias and is associated with a poor prognosis. Atrial arrhythmias and non-sustained ventricular arrhythmias are the most common arrhythmias in cardiac amyloidosis. However, the association of sinus node dysfunction and sustained ventricular arrhythmia is quite exceptional.

Case Presentation: A 59-year-old male patient was admitted with a gradually worsening dyspnea with a lipothymic discomfort. Upon emergency department, an initial electrocardiogram revealed a severe bradycardia related to a sinus node dysfunction. A transthoracic echocardiography and cardiac magnetic resonance imaging showed features suspicious for cardiac amyloidosis. The diagnosis of AL cardiac amyloidosis with multiple myeloma was confirmed based on histological evidence. During hospitalization, the patient presented a sustained unstable ventricular tachycardia which has been converted by electrical cardioversion. He was treated with an implantable cardioverter-defibrillator (ICD) for secondary prevention with one episode of appropriate therapy. Unfortunately, the patient died few weeks later.

Clinical Discussion: The AL subtype of cardiac amyloidosis is associated with higher rates of arrhythmias, especially VT. The management of arrhythmias in cardiac amyloidosis is complex and remains challenging given the lack of evidence. ICD was not associated with longer survival; these findings underscore the importance of careful patient selection for ICD.

Conclusion: As prognosis improves with the advances made in the medical treatment of cardiac amyloidosis, further studies are required to guide the management of all types of arrhythmias in cardiac amyloidosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793156PMC
http://dx.doi.org/10.1016/j.amsu.2022.104888DOI Listing

Publication Analysis

Top Keywords

cardiac amyloidosis
32
sinus node
12
node dysfunction
12
arrhythmias cardiac
12
cardiac
10
amyloidosis
9
sustained ventricular
8
ventricular arrhythmia
8
arrhythmias
7
arrhythmia sinus
4

Similar Publications

This post-marketing surveillance (PMS) assessed the safety and effectiveness of isatuximab plus pomalidomide and dexamethasone (Isa-Pd) for relapsed or refractory multiple myeloma (RRMM) in frail individuals during real-world use in Japan. Data from all individuals with RRMM treated with Isa-Pd in Japan between October 2020 and October 2021 were collected, with follow-up continued up to 12 months after starting Isa-Pd or until discontinuation. In the overall PMS population, 40 participants were classified as frail (33.

View Article and Find Full Text PDF

Waldenström macroglobulinemia is a rare cancer of plasma cells characterized by the excessive production of immunoglobulin M (IgM). IgM-associated systemic amyloid light chain (AL) amyloidosis is a rare complication of Waldenström macroglobulinemia, characterized by the misfolding of lambda light chains that deposit in various organs, including the heart. We describe a case of progressive nonischemic cardiomyopathy secondary to Waldenström macroglobulinemia and IgM-associated AL amyloidosis that was refractory to medical therapy and highlight the challenges in diagnosis and management.

View Article and Find Full Text PDF

Background: For the time being, tafamidis is the only approved treatment for wild-type transthyretin cardiac amyloidosis. However, benefits on all-cause death only emerge after ≈18 months. The current available staging systems are unable to specifically discriminate patients at high risk of death within 18 months from diagnosis, and the selection of patients who are expected to benefit from tafamidis is left to the clinical judgment of treating physicians, being often based primarily (and sometimes only) on age.

View Article and Find Full Text PDF

Amyloidosis is a rare disease that can affect genitourinary organs but the involvement of the prostate has been documented in a limited number of cases. We have reviewed morphologic and immunohistochemical features of prostate biopsies or surgical specimens in which an initial diagnosis of amyloidosis was made. Prostatic amyloidosis was diagnosed in 25 patients, 21 of them were needle biopsies (1.

View Article and Find Full Text PDF

Transthyretin amyloidosis (ATTR) is a rare disease that results in amyloid fibril misfolding and deposition in multiple organs, including the heart, leading to the development of ATTR cardiomyopathy (ATTR-CM), which is associated with poor outcomes. In the last decade, several disease-modifying medications are in advanced stages of clinical development or have been approved to treat ATTR-CM. The purpose of this review is to critically evaluate clinical trial data investigating the use of approved and investigational medications for the treatment of ATTR-CM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!